Crux Wealth Advisors Sells 86 Shares of Cencora, Inc. $COR

Crux Wealth Advisors reduced its stake in shares of Cencora, Inc. (NYSE:COR) by 3.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,101 shares of the company’s stock after selling 86 shares during the quarter. Crux Wealth Advisors’ holdings in Cencora were worth $630,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of COR. Price T Rowe Associates Inc. MD boosted its stake in shares of Cencora by 8.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock valued at $2,682,821,000 after purchasing an additional 787,858 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Cencora by 7.2% in the first quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock worth $1,507,599,000 after buying an additional 363,402 shares during the period. Boston Partners boosted its position in Cencora by 8.1% during the 1st quarter. Boston Partners now owns 5,411,193 shares of the company’s stock valued at $1,505,984,000 after acquiring an additional 404,093 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after acquiring an additional 1,364,433 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Cencora by 9.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock worth $475,890,000 after acquiring an additional 154,311 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. The trade was a 9.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the completion of the transaction, the chief executive officer directly owned 39,274 shares of the company’s stock, valued at approximately $11,389,460. The trade was a 11.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 51,025 shares of company stock valued at $14,831,784 in the last ninety days. 10.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms recently weighed in on COR. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Jefferies Financial Group boosted their target price on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a report on Monday, June 30th. Evercore ISI set a $340.00 target price on shares of Cencora in a research report on Wednesday, October 8th. Wells Fargo & Company lifted their price target on shares of Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research report on Wednesday, August 13th. Finally, Mizuho boosted their price objective on shares of Cencora from $316.00 to $334.00 and gave the stock an “outperform” rating in a research note on Thursday. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $324.91.

Cencora Stock Performance

NYSE:COR opened at $324.83 on Friday. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $325.70. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The firm has a market capitalization of $62.98 billion, a PE ratio of 33.42, a P/E/G ratio of 1.52 and a beta of 0.63. The stock has a 50-day simple moving average of $300.30 and a two-hundred day simple moving average of $293.23.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. During the same period in the previous year, the company posted $3.34 EPS. The firm’s revenue was up 8.7% on a year-over-year basis. Analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is 22.63%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.